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ABSTRACT
The immunosuppressive effect of ethyl O-(N-(p-
carboxyphenyl)-carbamoyl)-mycophenolate(CAM)
was examined in interphotoreceptor retinoid-binding
protein (IRBP)-induced experimental autoimmune uve-
oretinitis (EAU) in rats. Lewis rats immunized with
bovine IRBP were treated with various oral doses of
CAM postimmunization. The degree of inflammation
was assessed clinically each day and histologically on
day 14 or day 20. Production of various cytokines and
IRBP-specific antibody, as well as IRBP-specific prolifer-
ation response, was assessed. Complete inhibition of
EAU in rats, both by clinical and histologic criteria, was
achieved with 50 mg/kg CAM when administered
daily for 14 days following IRBP immunization. Partial
inhibition was observed at lesser doses of CAM. This
CAM-mediated response was accompanied by dimin-
ished production of cytokines interleukin-2, interferon-g
and tumor necrosis factor-a, as well as a reduction in
IRBP-specific antibody production. Furthermore, admin-
istration of CAM either in the induction phase only
(days 0–7) or in the effector phase only (days 9 or 11
to day 20) was also capable of suppressing EAU, as
assessed histopathologically on day 20. We conclude
that CAM is effective in suppressing EAU in rats and its
mechanism of action appears to involve modulation of
T cell function.
Key words: cytokine, experimental autoimmune uve-
oretinitis, immunosuppression, interphotoreceptor
retinoid-binding protein, mycophenolic acid.
INTRODUCTION
Experimental autoimmune uveoretinitis (EAU) has been
extensively studied as a model for human ocular inflam-
matory diseases, such as birdshot retinochoroidopathy,
sympathetic ophthalmia and Behçet’s disease.1–3 In
animals, EAU can be induced by immunization with 
interphotoreceptor retinoid-binding protein (IRBP), an
eye-specific retinal antigen, or by transfer of IRBP-specific
T cells.4,5 We have previously found that type 1 T helper
(Th1) cells are activated following IRBP immunization and
that transfer of these activated T cells can induce EAU
development.6 Furthermore, such Th1 cell-mediated
induction of EAU is counteracted by the activation of type
2 T helper (Th2) cells.6 These results have suggested that
EAU may be treated or its development prevented by the
manipulation of T cell activation.
Immunosuppressive drugs that impair T cell function,
such as cyclosporine A, FK506 and rapamycin, have
been used for the treatment of severe ocular inflamma-
tory diseases.7–10 However, these drugs are limited in their
use because of unwanted side effects, in particular the
hepatic and renal toxicity caused by cyclosporine A and
FK506.11,12 To achieve therapeutic results with minimal
side effects, an immunosuppressive drug with selective
action on lymphocytes would be useful. Ethyl O-(N-(p-
carboxyphenyl)-carbamoyl)-mycophenolate (CAM), a
derivative of mycophenolic acid (MPA) produced by
Penicillium brevicompactum, has been found to inhibit
immune responses as well as tumor cell growth.13
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Specifically, CAM has been shown to prolong cardiac
allografts in rats and to suppress the onset of experimen-
tal allergic encephalomyelitis (EAE) in rats.14,15 Following
in vivo administration, CAM is converted to mycopheno-
lic acid, which in turn exerts its effect by impairing the
activity of inosine monophosphate dehydrogenase
(IMPDH), an enzyme involved in purine metabolism.
Decreased IMPDH activity leads to depletion of GTP,
which is essential for lymphocyte activation.16
In the present study, we examined the effect of CAM on
IRBP-mediated EAU in rats. Severity of EAU inflammation
was assessed by clinical and histopathologic criteria and
production of various cytokines and IRBP-specific anti-
body, as well as the IRBP-specific proliferation response,
were measured.
METHODS
Rats
Male Lewis rats of 6–8 weeks of age were obtained from
Charles River Japan (Atsugi, Japan) and housed in our
specific pathogen-free animal facility. The animals were
treated in accordance with Guide for the Care and Use of
Laboratory Animals.17
Reagents
The CAM was obtained in powder form from Ajinomoto
Co. (Osaka, Japan). Bovine IRBP was purified using the
method described by Redmond et al.18 Other reagents
were all standard grade unless otherwise stated.
Induction and assessment of EAU
Rats were immunized with 50 µg bovine IRBP emulsified
in complete Freund’s adjuvant (Difco Laboratories,
Detroit, MI, USA), in one hind footpad in a total volume
of 0.1 mL. An additional adjuvant, Bordetella pertussis
bacteria (Wako Pure Chemical Industries, Osaka,
Japan), was concurrently injected intraperitoneally at a
dose of 1010 /rat. Following immunization, the rats were
examined daily by an independent observer using slit-
lamp biomicroscopy (Kowa, Tokyo, Japan). Eyes were
removed on day 14 or 20 after immunization and fixed in
10% buffered neutral formalin. Sections of samples were
embedded in paraffin and stained with hematoxylin and
eosin for histologic study. The clinical severity of EAU was
assessed by scoring three different criteria for a maximum
total score of 7 (Table 1). Similarly, the histologic severity
of EAU was assessed by scoring cellular infiltration in four
different areas and tissue destruction in three different
areas for a maximum total score of 14. Incidence was
expressed as number of EAU-positive rats out of the total
number of rats in each group, based on both clinical and
histologic examinations.
Administration of CAM
Suspensions of CAM were made in a 0.9% NaCl solution
containing 0.5% sodium carboxymethyl-cellulose, pro-
tected from light and preserved at 4°C. Aliquots from this
stock suspension of CAM were sonicated and diluted in
NaCl solution for each administration. Rats received a
daily oral gavage of 0, 10, 30 or 50 mg/kg CAM for dif-
ferent periods of time depending on the experiment as
follows: (i) entire observation period (day 0, day of IRBP
immunization, to day 14 or 20); (ii) induction phase (days
0–7); (iii) effector phase 1 (day 9, 1 day before the usual
onset of iridocyclitis in EAU, to day 20); and (iv) effector
phase 2 (day 11, after the onset of iridocyclitis had been
confirmed, to day 20). Control rats received equivalent
volumes of phosphate-buffered solution (PBS).
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Table 1 Scoring of clinical and histologic severity
Clinical scoring
Symptom Scale
Mydriasis after tropicamide instillation 0–2
0: Complete
1: Partial
2: Absent
Fibrin exudates in the anterior chamber 0–2
0: None
1: Limited to the pupillary margin
2: Covering the iris and pupil
Hypopyon 0–3
0: None
1: Mild
2: Moderate
3: Severe
Maximum total score 7
Histologic scoring
Cellular infiltration
Ciliary body 0–2
Retina 0–2
Choroid 0–2
Vitreous 0–2
Tissue destruction
Ciliary body 0–2
Retina 0–2
Choroid 0–2
Maximum total score 14
Measurement of cytokine production
Spleen cells (2 · 106/2 mL) from control rats and from
IRBP-immunized rats on day 20 that had or had not been
treated with CAM were cultured in the presence of
5 µg/mL IRBP for 24 h. Interleukin-2 and IL-6 activities
were then measured by biological assay using the murine
CTLL-2 and murine hybridoma MH60.BSF2 cell lines (gift
from Drs T Hirano and T Kishimoto), respectively.19 One
unit of IL-2 activity was defined as the concentration by
which a half-maximal [3H]-thymidine (TdR) uptake by
CTLL was induced. Concentrations of tumor necrosis
factor (TNF)-a and interferon (IFN)-g were measured by
specific enzyme-linked immunosorbent assay (ELISA) kits
(GIBCO Life-Technologies, Tokyo, Japan and COSMO
Bio., Tokyo, Japan).
Measurement of IRBP-specific lymphocyte 
proliferation
Spleens were removed on day 14 postimmunization and
single-cell suspensions were prepared. Cells at a density
of 2 · 105/well in 96-well plates were incubated in tripli-
cate in RPMI-1640 medium containing 10% fetal calf
serum, 5 · 10–5 mol/L 2-mercaptoethanol, and 50 µg/mL
kanamycin, with or without 5 µg/mL IRBP. [3H]-Thymidine
was added for the final 16 h of the 90 h incubation
period, followed by harvesting of cells and measurement
of [3H]-TdR uptake using a liquid scintillation counter.
Results were expressed as c.p.m., representing the mean
of at least three experiments with similar results.
Measurement of IRBP-specific serum IgG 
antibody formation by ELISA
Serum obtained from blood taken from the tail vein of
IRBP-immunized rats on day 14 was diluted 1:80 and
layered on to plates coated with 1 µg/mL IRBP (in carbon-
ate buffer, pH 9.5). Peroxidase-conjugated goat antirat
IgG antibody (Cappel, Organo Teknika Corp., West
Chester, PA, USA) was used as the secondary antibody.
Color was developed by adding o-phenylenediamine in a
0.01% H2O2 buffer and was assessed at 492 nm using an
ELISA autoreader (Colona, Tokyo, Japan).
Statistics
The Mann–Whitney U-test and Student’s t-test were used
for statistical analysis. Data are represented as the mean
± SEM.
RESULTS
Inhibition of IRBP-induced EAU mediated by
CAM
Lewis rats were immunized with 50 µg IRBP and then
administered either 50 mg/kg CAM or PBS (control) each
day by oral gavage from day 0 to day 14. Clinical exam-
ination was performed daily and eyes were removed on
day 14 for histologic examination. Generally, both eyes
of each rat developed EAU at about the same time and
with the same degree of severity. When a difference was
noted between the two eyes, the eye with the earlier onset
or greater severity was selected for use in evaluation.
Nine of nine control rats developed EAU, observed clini-
cally as iridocyclitis, on approximately day 10 (mean
9.8 ± 0.9 days) after IRBP immunization (Table 2). This
inflammation was subsequently confirmed histopatholog-
ically after enucleation on day 14 (Fig. 1a). In contrast,
treatment with CAM completely inhibited EAU develop-
ment, both clinically and pathologically, in 10 of 10 rats
(Fig. 1b).
Dose–response profile of CAM
In order to determine the dose–response profile of CAM
in inhibiting IRBP-mediated EAU, various doses of the
drug were administered from day 0 to day 20 (Table 3). A
significant delay in onset (10.3 ± 1.1 days) was accom-
panied by a decrease in inflammation (clinical score
3.8 ± 1.0) with 10 mg/kg CAM, compared with control
(onset at 8.0 ± 0.5 days and clinical score 6.0 ± 0.9).
Further improvement was obtained with 30 mg/kg CAM,
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Table 2 Inhibition of IRBP-induced EAU by CAM
Rats received a daily oral gavage of phosphate-buffered saline (PBS) or 50 mg/kg ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate
(CAM) from day 0, the day of interphotoreceptor retinoid-binding protein (IRBP) immunization, to day 14. Eyes were removed on day 14 after immu-
nization. *Number of rats that developed experimental autoimmune uveoretinitis (EAU). †The maximum score at the peak of inflammation is shown.
Treatment EAU* (day of onset) Clinical score† Pathologic score
PBS (control) 9/9 (9.8 ± 0.9) 5.5 ± 0.6 10.0 ± 0.6
CAM 0/10 0 0
with complete suppression of EAU development achieved
at a dose of 50 mg/kg. Pathologic scores correlated well
with clinical scores. These results indicate that CAM
inhibits EAU development in a dose-dependent manner.
Kinetics of CAM administration
To examine whether CAM acts in the early phase or in the
late phase of EAU development, rats were administered
50 mg/kg CAM at various intervals (Table 4).
Concomitant treatment with CAM during the first 8 days
(induction phase) caused a significant delay in onset
(13.8 ± 1.7 days) accompanied by a moderately dimin-
ished maximal clinical score (2.8 ± 0.5) compared with
the control (onset of 9.8 ± 0.9 days and clinical score
5.2 ± 0.9). Histopathologic examination of these rats on
day 20 showed little evidence of inflammation (Fig. 2a).
When rats that developed iridocyclitis by approximately
day 10 were treated with CAM during only the effector
phase (days 11–20), clinical inflammation was moder-
ately decreased (clinical score 3.0 ± 0.5) compared with
the control group (clinical score 5.2 ± 0.9), with almost
no inflammation observed on histopathologic examina-
tion. To further investigate the action of CAM on the
effector phase of EAU development, IRBP-immunized rats
were treated with 50 mg/kg CAM from days 9–20.
Treatment with CAM during this period of time resulted in
almost complete inhibition of uveoretinitis development,
although the clinical effect appeared to be less pro-
nounced (Table 4; Fig. 2b). These findings, taken
together, suggest that CAM affects both the effector and
induction phases of EAU development.
Inhibition of IRBP-induced cytokine production
in vitro mediated by CAM
T helper 1 cells or the cytokines they produce have been
reported to play a pivotal role in IRBP-induced EAU in
mice and rats.20,21 We, therefore, investigated whether
CAM affected such cytokine production in our experi-
ments. Treatment with 10 mg/kg CAM during the entire
observation period significantly suppressed production of
the cytokines IL-2, IFN-g and TNF-a , with more pro-
nounced suppression at a dose of 30 mg/kg and
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Fig. 1 Histopathology, on day 14, of the retina, of (a) a rat immunized with interphotoreceptor retinoid-binding protein (IRBP) that
did not receive ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate (CAM) treatment (control), showing widespread disorga-
nization with marked inflammatory cell infiltration, and (b) a rat immunized with IRBP that received 50 mg/kg CAM from days 0 to
14, showing no evidence of inflammation (original magnification · 130).
Table 3 Dose–response scores for CAM
Rats received a daily oral gavage of phosphate-buffered saline (PBS) or ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate (CAM) from
day 0 to day 20. Eyes were removed on day 20 after immunization. *Number of rats that developed experimental autoimmune uveoretinitis (EAU).
†The maximum score at the peak of inflammation is shown. ‡P < 0.01 compared with the control group, using the Mann–Whitney U-test.
Dose (mg/kg) EAU* (day of onset) Clinical score† Pathologic score
PBS (control) 6/6 (8.0 ± 0.5) 6.0 ± 0.9 11.4 ± 0.8
10 4/4 (10.3 ± 1.1) 3.8 ± 1.0‡ 6.8 ± 0.6‡
30 4/4 (13.5 ± 0.5) 1.3 ± 0.5‡ 2.0 ± 1.0‡
50 0/5 0 0
complete suppression at a dose of 50 mg/kg (Table 5).
Moreover, the production of IL-6 was also suppressed by
CAM treatment (Table 6). This CAM-mediated inhibition
of cytokine production correlates well with the inhibition
of EAU development clinically. Treatment with CAM
during the effector phase only also inhibited IRBP-
mediated IL-2 and IFN-g production, although treatment
during the induction phase alone did not show any signif-
icant inhibition.
Inhibition of IRBP- but not Con A-induced
spleen cell proliferation in vitro mediated by
CAM
We examined whether CAM also influences IRBP-induced
spleen cell proliferation in vitro. Spleen cells from IRBP-
immunized rats treated with 50 mg/kg CAM from days
0–14 were cultured in the presence of 5 µg/mL IRBP or
2.5 µg/mL concanavalin A (Con A; control). As shown in
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Table 4 Kinetics of CAM administration
Dose (50 mg/kg) was administered daily by oral gavage. Eyes were removed on day 20 after immunization. *Number of rats that developed
experimental autoimmune uveoretinitis (EAU). †The maximum score at the peak of inflammation is shown. ‡P < 0.01 compared with the control
group, using the Mann–Whitney U-test. CAM, ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate.
Fig. 2 Histopathology, on day 20, of the retina of (a) a rat immunized with interphotoreceptor retinoid-binding protein (IRBP) and
treated with 50 mg/kg ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate (CAM) from days 0 to 7 (induction phase),
showing little evidence of inflammation, and (b) a rat immunized with IRBP and treated with 50 mg/kg CAM from days 9 to 20 
(effector phase), showing a few inflammatory cells infiltrating the retina and choroid (original magnification · 130).
Table 5 Dose–response for CAM inhibition of IRBP-induced cytokine production in vitro
Rats received a daily oral gavage of phosphate-buffered saline (PBS) or ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate (CAM) from
day 0 to day 20. Eyes were removed on day 20 after immunization. *P < 0.01, †P < 0.05 compared with the control group using the Student’s 
t-test. IRBP, interphotoreceptor retinoid-binding protein; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor.
Period of CAM treatment EAU* (day of onset) Clinical score† Pathologic score
None (control) 13/13 (9.8 ± 0.9) 5.2 ± 0.9 8.6 ± 0.7
Day 0–7 6/7 (13.8 ± 1.7) 2.8 ± 0.5‡ 0.5 ± 0.5‡
Day 9–20 4/6 (10.5 ± 0.8) 2.5 ± 0.4‡ 0.5 ± 0.5‡
Day 11–20 5/5 (9.8 ± 0.7) 3.0 ± 0.5‡ 0.5 ± 0.5‡
Dose (mg/kg) Cytokine
IL-2 (U/mL) IFN- g (ng/mL) TNF-a (ng/mL)
PBS (control) 43 ± 4 222.0 ± 26.0 10.8 ± 1.0
10 11 ± 1* 128.9 ± 47.1† 7.8 ± 1.4
30 < 1* 60.4 ± 10.5* 4.0 ± 0.7†
50 < 1* < 1.0* < 1.0*
Fig. 3, IRBP-induced spleen cell proliferation was dramat-
ically inhibited by CAM, whereas Con A-induced spleen
cell proliferation was unchanged. These results suggest
that CAM suppression of IRBP-induced lymphocyte acti-
vation is not due to non-specific inactivation of T cell
function.
Inhibition of anti-IRBP antibody production by
CAM in vivo
To examine whether CAM also inhibits anti-IRBP antibody
production in vivo, sera obtained from mice immunized
with IRBP and then treated with 50 mg/kg CAM from
days 0–14 were assayed by ELISA. As shown in Fig. 4,
CAM completely suppressed IRBP-specific IgG antibody
production in rats, suggesting that the drug inhibits
humoral immune responses in EAU as well.
DISCUSSION
In the present study, the oral administration of CAM was
shown to suppress IRBP-mediated EAU in rats in a dose-
dependent manner. Cytokine production, which appears
to play an important role in IRBP-mediated EAU,22 is
inhibited by CAM treatment given during the effector
phase only, as well as for the entire period. As expected,
partial treatment with CAM was somewhat less effective
than treatment for the entire period, especially when
assessed by the clinical degree of iridocyclitis.
Suppression of IRBP-induced production of cytokines,
such as IL-2 and IFN-g , by CAM correlated well with the
suppression of EAU, although no measurable effect on 
IL-2 and IFN-g production was detected with CAM
administered during the induction phase only. Treatment
with CAM suppressed IRBP-induced spleen cell prolifera-
tion, while Con A-induced proliferation remained largely
intact, suggesting that CAM does not affect lymphocyte
function non-specifically.
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Table 6 In vitro inhibition by CAM of IRBP-induced cytokine production
Dose (50 mg/kg) was administered daily by oral gavage. *P < 0.01 compared with the control group using the Student’s t-test.
Fig. 3 Lymphocyte proliferation response under the stimula-
tion of interphotoreceptor retinoid-binding protein (IRBP), 5 m g
or concanavalin A (Con A), 2.5 m g in experimental auto-
immune uveoretinitis rats with (j; n = 5) or without (h; n = 6)
ethyl O-(N-(p-carboxyphenyl)-carbamoyl)-mycophenolate treat-
ment. Spleen cells were obtained on day 14 after immunization.
Bars represent one standard error.
Fig. 4 Interphotoreceptor retinoid-binding protein-specific
serum immunoglobulin G antibody was measured by enzyme-
linked immunosorbent assay on day 14 with (h; n = 6) or
without (j; n = 5) CAM treatment. Bars represent one stan-
dard error.
Period of CAM treatment Cytokine
IL-2 (U/mL) IFN- g (ng/mL) IL-6 (ng/mL)
Control 85 ± 6 82.4 ± 5.3 18.4 ± 2
Days 0–20 4 ± 1* 15.6 ± 3.2* 2.1 ± 1*
(entire period)
Days 0–7 83 ± 7 65.0 ± 5.1 15.8 ± 3
(induction phase only)
Days 11–20 < 1* < 1.0* Not done
(effector phase only)
Following oral administration, CAM is immediately
metabolized to MPA.23 To check whether the MPA con-
centration achieved in vivo is therapeutically effective,
plasma MPA levels have previously been measured at
various times following CAM administration. The plasma
level of MPA reaches 10 µg/mL at 1 h after administra-
tion and remains above this level for the first 8 h. At 24 h,
the MPA concentration was still greater than 4 µg/mL, a
level reported to be sufficient for inhibiting induction of
hemolytic plaque-forming cells against sheep red blood
cell antigen in vitro.23 This indicates that an effective con-
centration of CAM is, indeed, obtained through oral
administration.
Originally, CAM was developed for the treatment of
tumors,23 but because of its immunosuppressive activity24
it has recently been used for the prevention of graft rejec-
tion in cardiac transplantation.14 The action of CAM
appears to be relatively restricted to lymphocytes,
because these cells mainly use the de novo pathway of
purine synthesis, which is inhibited by the CAM metabo-
lite MPA.16 Cells other than lymphocytes can use both the
salvage and de novo pathways for DNA synthesis and
therefore are not affected by MPA. Because of its selective
effects on lymphocytes, CAM is an ideal agent to be 
used in autoimmune disease processes without causing
serious side effects. Indeed, no apparent adverse effects
have been observed in this study. Furthermore, in a phase
I clinical trial for the treatment of gastric cancer and
leukemia, the only side effect of CAM observed was mild
gastrointestinal discomfort; there was no adverse effect
on hepatic or renal function.25 A water-soluble form of
CAM has also been developed and tested in a separate
study as a topical ophthalmic solution for the treatment of
uveitis, with encouraging results.26 Mycophenolate
mofetil (MM), another derivative of MPA, has also been
shown to inhibit the development of EAU.27 However,
CAM may be more effective than MM in EAU, because
EAU could be completely inhibited by CAM at high doses
in our present study. In addition, CAM has previously
been found to be more effective than MM in a study of rat
cardiac transplantation.14 It has been suggested that the
increased bioavailability of CAM contributes to a pro-
longed effective plasma level when compared with MM.
CD4+ T helper cells are classified into Th1 and Th2
cells according to their profile of cytokine production.28
The balance between Th1 and Th2 cells plays a major
role in determining the outcome of immune responses.
Activation of Th1 cells promotes a cell-mediated immune
response, while activation of Th2 cells promotes a
humoral immune response. We have shown that IRBP-
specific Th1 cells play a pivotal role in EAU development
in mice and that these cells are down-regulated by IRBP-
specific Th2 cells.6 In the present study, we have found
that CAM inhibits the cytokine production profiles of both
types of cells, because IL-2 and IFN-g are produced 
by Th1 cells, while IL-6 is produced by Th2 cells.
Furthermore, we have found that anti-IRBP-specific anti-
body production is also inhibited by CAM treatment,
consistent with the inhibition of Th2 cells. In the future, it
is likely that CAM will become available for use as an
immunosuppressive agent with efficacy in both Th1-type
autoimmune diseases (e.g. organ-specific autoimmune
disease) and Th2-type autoimmune diseases (e.g.
allergy).
Treatment with CAM during only the induction phase
or only the effector phase dramatically abolishes the
development of IRBP-induced EAU, as assessed histologi-
cally. The extent of this inhibition of EAU is almost the
same as that for CAM treatment during the entire period.
Inhibition of EAU mediated by CAM correlates well with
the suppression of IRBP-induced cytokine production and
lymphocyte proliferation. These results are consistent with
the finding that cytokines produced by uveitogenic T cell
lines play a pivotal role in EAU development.6 Curiously,
although rats administered CAM during only the induc-
tion phase achieved inhibition of EAU, the production of
IL-2, IFN- g or IL-6 was not markedly suppressed when
assayed using spleen cells taken on day 20 after IRBP
immunization. These results suggest that IRBP-specific T
cells are not deleted by CAM treatment. Rather, it may be
that IRBP-specific T cells are being recruited from a pre-
cursor pool. This would agree with the finding that the
action of CAM is reversible. In data not shown, EAU
development in three of three rats was completely inhib-
ited by CAM at day 20. However, after stopping CAM
treatment and re-immunizing with IRBP on day 20, two of
three rats developed inflammation. This suggests that
CAM cannot induce immune tolerance in this EAU
model. It appears that EAU is largely inhibited by treat-
ment with CAM during only the induction phase, with
lymphocyte activation during this induction phase being
essential to the pathogenesis of EAU. Mizoguchi et al.
have reported that CAM administered during only the
induction phase inhibits EAE in rats induced by spinal
cord homogenates.15
Iridocyclitis is observed at approximately day 10 
following IRBP immunization, both clinically and histo-
pathologically. However, no evidence of posterior pole
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inflammation is found at this point. Retinitis is first
observed at around day 14, suggesting that further cellu-
lar events take place between day 10 and day 14.29
These events may be sensitive to CAM, because treat-
ment during the effector phase only (days 11–20) still
inhibits the development of retinitis. Treatment with CAM
during only the effector phase also suppresses both IL-2
and IFN-g production, further supporting a role for Th1-
derived cytokines in the development of EAU. It has been
suggested that CAM may inhibit lymphocyte proliferation,
cytokine production and antibody formation under stimu-
lation by specific antigen only during the period of drug
administration. Based on the data of the present study, it
is unclear whether CAM suppression of IRBP-induced
lymphocyte activation is antigen specific, although from
Fig. 3 we speculate that it is. Moreover, antigen specificity
is supported by work in the rat cardiac transplantation
model, which has shown the development of CAM-
induced antigen-specific tolerance.14
In summary, our results indicate that the novel
immunosuppressive drug CAM inhibits IRBP-mediated
EAU development and that this is accompanied by a
decrease in cytokine production. It appears that CAM has
only minor adverse side effects, due to its relatively spe-
cific action on lymphocytes, and thus has the potential for
long-term usage. Furthermore, the finding that CAM also
acts in the effector phase of EAU suggests that CAM may
be useful in the clinical setting as a therapy for ocular
inflammatory diseases.
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